When we investigated ERα/Src and ERα/PI3K interactions on the fixed tumours from the different treatments, we found that fulvestrant triggers a strong decrease in both interactions, consistent with the fulvestrant-induced ERα degradation. The gene discussed is SRC; the disease is neoplasm.